Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 265 participants.

Also called NCT03767543

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 265 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03767543
Other papers using this trial's data
  • Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial Diabetes, obesity & metabolism, 2022-10 DOI, PubMed 35670659, PMC9546064 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03767543. Randomized; no masking; primary purpose treatment. Start 2019-03-11 (actual); primary completion 2020-10-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
Acronym
LixilanOne CAN
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03767543
Content hash
e1b90688aacc4151d250290b109e8629cdd219c583d573f93309251c1965006f